The Oncopanel Pilot (TOP) Study

Plain-language summary

This pilot study evaluates the use of a genomic tumor panel (Oncopanel) to guide testing in patients with various advanced cancers. Patients with archival tumor tissue and known invasive cancers eligible for standard genetic testing (such as KRAS in colorectal cancer, EGFR in lung cancer, and BRAF in melanoma) were able to take part. It was conducted as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

British Columbia Cancer Agency

Start date

10/1/2014

Estimated completion

3/1/2017

Countries

Canada

Related genes

Locations

• Abbotsford British Columbia, Canada
• Kelowna, Canada
• Surrey, Canada
• Vancouver, Canada
• Victoria, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Patients with archival tumor tissue and a known history of invasive malignancies are eligible if they meet one or more of the following criteria:

* Advanced colorectal cancer and eligible for standard KRAS testing,
* Advanced non-small cell lung cancer and eligible for standard EGFR testing,
* Advanced melanoma and eligible for standard BRAF testing,
* Gastrointestinal stromal tumors (GISTs) eligible for standard c-KIT and PDGFRA testing,
* Being considered for potential eligibility in clinical trial.